Isokaempferide

Isokaempferide

SCHEMBL1628023

COc1c(-c2ccc(O)cc2)oc2cc(O)cc(O)c2c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 4/20 1.00
CYP3A4 P08684 3/20 1.00
CYP2D6 P10635 3/20 1.00
KDM4E B2RXH2 3/20 1.00
POLB P06746 2/20 1.00
APEX1 P27695 2/20 1.00
RECQL P46063 2/20 1.00
MCL1 Q07820 1/20 1.00
ABCB1 P08183 7/20 0.83
MAPT P10636 3/20 0.81
MEN1 O00255 2/20 0.81
KMT2A Q03164 2/20 0.81
HSD17B10 Q99714 2/20 0.81
MMP1 P03956 1/20 0.81
GAA P10253 1/20 0.81
HTT P42858 1/20 0.81
BLM P54132 1/20 0.81
TUBB4A P04350 2/20 0.77
TUBB P07437 2/20 0.77
TUBA3C P0DPH7 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isokaempferide SCHEMBL29721227 1.00 POLH (1.00) POLHCYP3A4CYP2D6KDM4EPOLB
Ermanin SCHEMBL2875089 0.92 CYP3A4 (1.00) POLHCYP3A4CYP2D6KDM4EPOLB
SCHEMBL3188065 0.91 POLH (0.83) POLHCYP3A4CYP2D6KDM4EPOLB
SCHEMBL15361036 0.91 POLH (0.83) POLHCYP3A4CYP2D6KDM4EPOLB
SCHEMBL11096105 0.91 POLH (0.83) POLHCYP3A4CYP2D6KDM4EPOLB
SCHEMBL4631662 0.91 ABCB1 (1.00) POLHCYP3A4CYP2D6KDM4EPOLB
Kumatakenin SCHEMBL3351483 0.91 KDM4E (0.83) POLHCYP3A4CYP2D6KDM4EPOLB
Kumatakenin SCHEMBL29681818 0.91 KDM4E (0.83) POLHCYP3A4CYP2D6KDM4EPOLB
SCHEMBL2284176 0.90 CYP3A4 (0.81) POLHCYP3A4CYP2D6KDM4EPOLB
3-O-Methylquercetin SCHEMBL380558 0.90 POLH (1.00) POLHCYP3A4CYP2D6KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12514278-B2 Tobacco-derived composition R.J. REYNOLDS TOBACCO COMPANY (US) 2026-01-06 US claimed
US-20220346435-A1 TOBACCO-DERIVED COMPOSITION REYNOLDS TOBACCO CO R (US) 2022-11-03 US claimed
CN-110432537-B Tobacco-derived O-methylated flavonoid compositions R.J.雷诺兹烟草公司 2022-08-19 CN claimed
US-11412775-B2 Tobacco-derived composition R.J. REYNOLDS TOBACCO COMPANY (US) 2022-08-16 US claimed
EP-2906055-B1 METHOD OF EXTRACTING TOBACCO-DERIVED O-METHYLATED FLAVONOID AND USE THEREOF REYNOLDS TOBACCO CO R (US) 2020-12-16 EP claimed
CN-110432537-A The flavonoid composition of the methylation of O- derived from tobacco REYNOLDS TOBACCO CO R 2019-11-12 CN claimed
EP-2906055-A1 TOBACCO-DERIVED O-METHYLATED FLAVONOID COMPOSITION R. J. Reynolds Tobacco Company (US) 2015-08-19 EP claimed
CN-104780791-A Tobacco-derived O-methylated flavonoid compositions REYNOLDS TOBACCO CO R 2015-07-15 CN claimed
US-20140096780-A1 TOBACCO-DERIVED COMPOSITION R.J. REYNOLDS TOBACCO COMPANY (US) 2014-04-10 US claimed
EP-1781235-B1 ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH WHOLESOME LIFE SCIENCE CO LTD (TW) 2013-12-25 EP claimed
US-7588788-B2 administering a ginger extracts from the root of Zingiber zerumbet Sm to treat an allergic rhinitis, asthma and eczema; nutraceuticals as antiinflammatory agents WHOLESOME LIFE SCIENCE CO., LTD. (TW) 2009-09-15 US claimed
EP-1781235-A4 ANTI-HYPERSENSITIVE INFLAMMATION AND ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH WHOLESOME LIFE SCIENCE CO LTD (TW) 2008-07-02 EP claimed
EP-1781235-A1 ANTI-HYPERSENSITIVE INFLAMMATION AND ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH Wholesome Life Science Co., Ltd. (TW) 2007-05-09 EP claimed
US-20060083799-A1 Anti-hypersensitive inflammation and anti-allergy activities of Zingiber zerumbet (L.) Smith WHOLESOME LIFE SCIENCE CO., LTD. 2006-04-20 US claimed
WO-2006020246-A1 ANTI-HYPERSENSITIVE INFLAMMATION AND ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH LIN TSUNG-CHUNG (US) 2006-02-23 WO claimed
WO-2003026705-A1 METHODS FOR STERILIZING BIOLOGICAL MATERIALS USING FLAVONOID/FLAVONOL STABILIZERS CLEARANT, INC. (US) 2003-04-03 WO claimed
US-20030059338-A1 Methods for sterilizing biological materials using flavonoid/flavonol stabilizers CLEARANT, INC. 2003-03-27 US claimed
US-4774229-A ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT CHEMEX PHARMACEUTICALS, INC. (US) 1988-09-27 US claimed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 WO claimed
US-20260117236-A1 METHODS AND COMPOSITIONS FOR MODULATING TRICHOME DENSITY AND FLAVOR MOLECULE SECRETION ALTRIA CLIENT SERVICES LLC (US) 2026-04-30 US disclosed
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities THE BROAD INSTITUTE, INC. (US) 2026-03-17 US disclosed
US-12514278-B2 Tobacco-derived composition R.J. REYNOLDS TOBACCO COMPANY (US) 2026-01-06 US disclosed
US-20250376656-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-11 US disclosed
EP-4580594-A1 ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) 2025-07-09 EP disclosed
CN-120078850-A Sargentodoxa cuneata-herba patriniae extract, and pharmaceutical composition and application thereof 扬州大学 2025-06-03 CN disclosed
US-20240368614-A1 Composition and Methods for Producing Tobacco Plants and Products Having Increased Phenylalanine and Reduced Tobacco-Specific Nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC (US) 2024-11-07 US disclosed
US-11999961-B2 Composition and methods for producing tobacco plants and products having increased phenylalanine and reduced tobacco-specific nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC (US) 2024-06-04 US disclosed
EP-4062774-B1 COMPOSITION AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING INCREASED PHENYLALANINE AND REDUCED TOBACCO-SPECIFIC NITROSAMINES (TSNAS) ALTRIA CLIENT SERVICES LLC (US) 2024-03-20 EP disclosed
WO-2024046834-A1 ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS ANALYTICON DISCOVERY GMBH (DE) 2024-03-07 WO disclosed
EP-4331564-A1 ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS Analyticon Discovery GmbH (DE) 2024-03-06 EP disclosed
CN-115554347-B Virus inhibitor and preparation method and application thereof 河南农业大学 2023-09-19 CN disclosed
CN-111511406-B Challenge test for diagnosing autism spectrum disease subtypes 斯大利卡拉公司 2023-04-28 CN disclosed
CN-115896007-A Application of chrysoeriol in preparation of products for promoting embryonic development 五邑大学 2023-04-04 CN disclosed
CN-115554347-A Virus inhibitor and preparation method and application thereof 河南农业大学 2023-01-03 CN disclosed
US-20220403402-A1 Composition and Methods for Producing Tobacco Plants and Products Having Increased Phenylalanine and Reduced Tobacco-Specific Nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC (US) 2022-12-22 US disclosed
US-20220346435-A1 TOBACCO-DERIVED COMPOSITION REYNOLDS TOBACCO CO R (US) 2022-11-03 US disclosed
EP-4062774-A1 COMPOSITION AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING INCREASED PHENYLALANINE AND REDUCED TOBACCO-SPECIFIC NITROSAMINES (TSNAS) Altria Client Services LLC (US) 2022-09-28 EP disclosed
CN-110432537-B Tobacco-derived O-methylated flavonoid compositions R.J.雷诺兹烟草公司 2022-08-19 CN disclosed
US-11412775-B2 Tobacco-derived composition R.J. REYNOLDS TOBACCO COMPANY (US) 2022-08-16 US disclosed
US-20220228190-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-07-21 US disclosed
US-11377665-B2 Composition and methods for producing tobacco plants and products having increased phenylalanine and reduced tobacco-specific nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC (US) 2022-07-05 US disclosed
EP-3773017-B1 COMPOSITION AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING INCREASED PHENYLALANINE AND REDUCED TOBACCO-SPECIFIC NITROSAMINES (TSNAS) ALTRIA CLIENT SERVICES LLC (US) 2022-06-08 EP disclosed
CN-111603496-B Suspension artemisia rupestris total flavone nano inclusion preparation and preparation method and application thereof 新疆维吾尔自治区药物研究所 2022-04-22 CN disclosed
WO-2022021780-A1 MEDICATED DIET AND DIETARY THERAPY COMPOSITION FOR TYPE 2 DIABETES AND PREPARATION METHOD THEREFOR 深圳市老年医学研究所 2022-02-03 WO disclosed
US-20210228540-A1 KAEMPFEROL ANALOG-CONTAINING COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-07-29 US disclosed
WO-2021024041-A1 CONTROLLED RELEASE DRUG DIMERS RIPPLE THERAPEUTICS CORPORATION (CA) 2021-02-11 WO disclosed
EP-2906055-B1 METHOD OF EXTRACTING TOBACCO-DERIVED O-METHYLATED FLAVONOID AND USE THEREOF REYNOLDS TOBACCO CO R (US) 2020-12-16 EP disclosed
US-20200323816-A1 KAEMPFEROL ANALOG-CONTAINING COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-10-15 US disclosed
US-10744114-B2 Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity OSTEONEUROGEN INC. (KR) 2020-08-18 US disclosed
US-10744113-B2 Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity OSTEONEUROGEN INC. (KR) 2020-08-18 US disclosed
WO-2020127888-A2 URBAN DARKENING SKIN COMPOSITION AND FORMULATION ORIFLAME COSMETICS AG (CH) 2020-06-25 WO disclosed
CN-107412109-B Allergy-relieving scalp care solution 拉芳家化股份有限公司 2020-01-17 CN disclosed
CN-110432537-A The flavonoid composition of the methylation of O- derived from tobacco REYNOLDS TOBACCO CO R 2019-11-12 CN disclosed
US-20190300893-A1 Composition and Methods for Producing Tobacco Plants and Products Having Increased Phenylalanine and Reduced Tobacco-Specific Nitrosamines (TSNAs) ALTRIA CLIENT SERVICES LLC (US) 2019-10-03 US disclosed
US-20190231739-A1 NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY OSTEONEUROGEN INC. (KR) 2019-08-01 US disclosed
US-20170239211-A1 USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY OSTEONEUROGEN INC. (KR) 2017-08-24 US disclosed
US-20170239211-A1 USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY OSTEONEUROGEN INC. (KR) 2017-08-24 US disclosed
EP-2906055-A1 TOBACCO-DERIVED O-METHYLATED FLAVONOID COMPOSITION R. J. Reynolds Tobacco Company (US) 2015-08-19 EP disclosed
CN-104780791-A Tobacco-derived O-methylated flavonoid compositions REYNOLDS TOBACCO CO R 2015-07-15 CN disclosed
US-20140096780-A1 TOBACCO-DERIVED COMPOSITION R.J. REYNOLDS TOBACCO COMPANY (US) 2014-04-10 US disclosed
EP-1781235-B1 ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH WHOLESOME LIFE SCIENCE CO LTD (TW) 2013-12-25 EP disclosed
US-8299119-B2 Biologically active compounds Bio-Active Export Pty. Ltd. (AU) 2012-10-30 US disclosed
US-8299119-B2 Biologically active compounds Bio-Active Export Pty. Ltd. (AU) 2012-10-30 US disclosed
US-8299119-B2 Biologically active compounds Bio-Active Export Pty. Ltd. (AU) 2012-10-30 US disclosed
US-8017147-B2 Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance MAZED MOHAMMAD A 2011-09-13 US disclosed
US-20110091353-A1 Methods for Sterilizing Tissue BURGESS WILSON 2011-04-21 US disclosed
CN-101982465-A Flavonoid compound extracted from liquorice and preparation method and application thereof NINGXIA INST FOR DRUG CONTROL 2011-03-02 CN disclosed
US-7888388-B2 Peroxisome proliferator activated receptor ligand and process for producing the same KANEKA CORPORATION (JP) 2011-02-15 US disclosed
US-7888388-B2 Peroxisome proliferator activated receptor ligand and process for producing the same KANEKA CORPORATION (JP) 2011-02-15 US disclosed
US-20100021533-A1 NUTRITIONAL SUPPLEMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE, DIABETES, AND REGULATION AND REDUCTION OF BLOOD SUGAR AND INSULIN RESISTANCE MAZED MOHAMMAD A 2010-01-28 US disclosed
US-7604823-B2 Synergistic HIV/AIDS and/or immune disease phyto-nutraceutical composition Olalde Rangel, Jose Angel (US) 2009-10-20 US disclosed
US-20090252796-A1 NUTRITIONAL SUPPLEMENT FOR THE PREVENTION OF CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE, DIABETES, AND REGULATION AND REDUCTION OF BLOOD SUGAR AND INSULIN RESISTANCE MAZED MOHAMMAD A 2009-10-08 US disclosed
US-7588788-B2 administering a ginger extracts from the root of Zingiber zerumbet Sm to treat an allergic rhinitis, asthma and eczema; nutraceuticals as antiinflammatory agents WHOLESOME LIFE SCIENCE CO., LTD. (TW) 2009-09-15 US disclosed
US-7588788-B2 administering a ginger extracts from the root of Zingiber zerumbet Sm to treat an allergic rhinitis, asthma and eczema; nutraceuticals as antiinflammatory agents WHOLESOME LIFE SCIENCE CO., LTD. (TW) 2009-09-15 US disclosed
US-20090221517-A1 Biologically Active Compounds BIO-ACTIVES EXPORT PTY., LTD. 2009-09-03 US disclosed
US-20090221517-A1 Biologically Active Compounds BIO-ACTIVES EXPORT PTY., LTD. 2009-09-03 US disclosed
US-20090221517-A1 Biologically Active Compounds BIO-ACTIVES EXPORT PTY., LTD. 2009-09-03 US disclosed
US-20090214382-A1 Methods of sterilizing biological mixtures using alpha-keto acids CLEARANT, INC. 2009-08-27 US disclosed
US-7563467-B2 Use of an Opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-07-21 US disclosed
US-7553501-B2 Immune phyto-neutraceutical composition Olalde Rangel, Jose Angel (US) 2009-06-30 US disclosed
US-7524975-B2 Peroxisome proliferator activated receptor ligand and process for producing the same KANEKA CORPORATION (JP) 2009-04-28 US disclosed
US-7524975-B2 Peroxisome proliferator activated receptor ligand and process for producing the same KANEKA CORPORATION (JP) 2009-04-28 US disclosed
US-20090036519-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGAND AND PROCESS FOR PRODUCING THE SAME KANEKA CORPORATION (JP) 2009-02-05 US disclosed
US-20090036519-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGAND AND PROCESS FOR PRODUCING THE SAME KANEKA CORPORATION (JP) 2009-02-05 US disclosed
EP-1448188-A4 USE OF AN OPUNTIA FICUS-INDICA EXTRACT AND COMPOUNDS ISOLATED THEREFROM FOR PROTECTING NERVE CELLS KOREA INST SCI & TECH (KR) 2008-11-26 EP disclosed
EP-1963350-A1 BIOLOGICALLY ACTIVE COMPOUNDS BIO-ACTIVES EXPORT PTY. LTD. (AU) 2008-09-03 EP disclosed
WO-2008100977-A2 CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS N.V. ORGANON (NL) 2008-08-21 WO disclosed
EP-1781235-A4 ANTI-HYPERSENSITIVE INFLAMMATION AND ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH WHOLESOME LIFE SCIENCE CO LTD (TW) 2008-07-02 EP disclosed
US-20080118582-A1 Synergistic Inmune Phyto-Nutraceutical Composition OLALDE RANGEL JOSE ANGEL 2008-05-22 US disclosed
US-20080080998-A1 Propylene glycol, dimethyl sulfoxide, trehalose and mannitol and gamma radiation; reduce active biological contaminants or pathogens in bone; reduce post-implantation complications, inflammation, immune rejection reactions, calcification CLEARANT, INC. 2008-04-03 US disclosed
US-20080063658-A1 SYNERGISTIC HIV/AIDS AND/OR IMMUNE DISEASE PHYTO-NUTRACEUTICAL COMPOSITION OLALDE RANGEL JOSE ANGEL 2008-03-13 US disclosed
US-20080009451-A1 Applications of kidney secreted bone growth factor and pharmaceutical use of flavonol and flavonol glycosides for stimulating the secretion of kidney secreted bone growth factor LONG MIAN 2008-01-10 US disclosed
WO-2007062468-A1 BIOLOGICALLY ACTIVE COMPOUNDS BIO-ACTIVES EXPORT PTY. LTD. (AU) 2007-06-07 WO disclosed
EP-1781235-A1 ANTI-HYPERSENSITIVE INFLAMMATION AND ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH Wholesome Life Science Co., Ltd. (TW) 2007-05-09 EP disclosed
US-7211567-B1 Composition for preventing and treating type I allergy SUNSTAR, INC. (JP) 2007-05-01 US disclosed
US-20060083799-A1 Anti-hypersensitive inflammation and anti-allergy activities of Zingiber zerumbet (L.) Smith WHOLESOME LIFE SCIENCE CO., LTD. 2006-04-20 US disclosed
WO-2006020246-A1 ANTI-HYPERSENSITIVE INFLAMMATION AND ANTI-ALLERGY ACTIVITIES OF ZINGIBER ZERUMBET (L.) SMITH LIN TSUNG-CHUNG (US) 2006-02-23 WO disclosed
EP-1618412-A2 DEVICES AND METHODS FOR DETERMINING THE AMOUNT OF ENERGY ABSORBED DURING IRRADIATION Clearant, Inc. (US) 2006-01-25 EP disclosed
US-6979829-B2 Devices and methods for determining the amount of energy absorbed during irradiation CLEARANT INC. (US) 2005-12-27 US disclosed
US-6908591-B2 Methods for sterilizing biological materials by irradiation over a temperature gradient CLEARANT, INC. (US) 2005-06-21 US disclosed
EP-1539254-A2 METHODS FOR STERILIZING BIOLOGICAL MATERIALS BY IRRADIATION OVER A TEMPERATURE GRADIENT Clearant, Inc. (US) 2005-06-15 EP disclosed
US-20050106728-A1 Methods of sterilizing biological mixtures using stabilizer mixtures CLEARANT INC. 2005-05-19 US disclosed
US-20050069453-A1 Methods for sterilizing preparations of urokinase CLEARANT, INC. 2005-03-31 US disclosed
US-20050042311-A1 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells AGRICULTURAL CORPORATIVE SE.JONG CO. (KR) 2005-02-24 US disclosed
WO-2004095062-A2 DEVICES AND METHODS FOR DETERMINING THE AMOUNT OF ENERGY ABSORBED DURING IRRADIATION CLEARANT, INC. (US) 2004-11-04 WO disclosed
US-20040211916-A1 Devices and methods for determining the amount of energy absorbed during irradiation CLEARANT INC. 2004-10-28 US disclosed
EP-1448188-A1 USE OF AN OPUNTIA FICUS-INDICA EXTRACT AND COMPOUNDS ISOLATED THEREFROM FOR PROTECTING NERVE CELLS Korea Institute of Science and Technology (KR) 2004-08-25 EP disclosed
US-20040091388-A1 Methods for sterilizing biological materials by multiple rates CLEARANT, INC. 2004-05-13 US disclosed
US-20040086420-A1 Methods for sterilizing serum or plasma CLEARANT, INC. 2004-05-06 US disclosed
US-20040033160-A1 Methods for sterilizing biological materials by irradiation over a temperature gradient CLEARANT, INC. 2004-02-19 US disclosed
WO-2004009137-A2 METHODS FOR STERILIZING BIOLOGICAL MATERIALS BY IRRADIATION OVER A TEMPERATURE GRADIENT CLEARANT, INC. (US) 2004-01-29 WO disclosed
WO-2004009143-A1 METHODS FOR STERILIZING BIOLOGICAL MATERIALS BY MULTIPLE RATES CLEARANT, INC. (US) 2004-01-29 WO disclosed
US-6682695-B2 GAMMA IRRADIATING FETAL BOVINE SERUM AT VARIED DOSAGES CLEARANT, INC. 2004-01-27 US disclosed
WO-2003092745-A1 METHODS FOR STERILIZING TISSUES USING CRYOPRESERVATIVES CLEARANT, INC. (US) 2003-11-13 WO disclosed
US-20030185702-A1 Methods for sterilizing tissue CLEARANT, INC. 2003-10-02 US disclosed
US-20030180181-A1 Methods for sterilizing tissue CLEARANT, INC. 2003-09-25 US disclosed
US-20030162163-A1 Method of sterilizing heart valves CLEARANT, INC. 2003-08-28 US disclosed
US-20030161753-A1 Methods for sterilizing biological materials by multiple rates CLEARANT, INC. 2003-08-28 US disclosed
WO-2003065802-A1 METHODS FOR STERILIZING TISSUE CLEARANT, INC. (US) 2003-08-14 WO disclosed
WO-2003059146-A2 METHOD OF STERILIZING HEART VALVES CLEARANT, INC. (US) 2003-07-24 WO disclosed
US-20030124023-A1 Method of sterilizing heart valves CLEARANT, INC. 2003-07-03 US disclosed
WO-2003037324-A1 USE OF AN OPUNTIA FICUS-INDICA EXTRACT AND COMPOUNDS ISOLATED THEREFROM FOR PROTECTING NERVE CELLS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2003-05-08 WO disclosed
WO-2003035238-A2 METHODS FOR COMBATING BIO-TERRORISM CLEARANT, INC. (US) 2003-05-01 WO disclosed
WO-2003030949-A1 METHODS OF STERILIZING BIOLOGICAL MATERIALS CLEARANT INC. (US) 2003-04-17 WO disclosed
US-20030064000-A1 Methods of sterilizing biological mixtures using stabilizer mixtures CLEARANT, INC. 2003-04-03 US disclosed
WO-2003026705-A1 METHODS FOR STERILIZING BIOLOGICAL MATERIALS USING FLAVONOID/FLAVONOL STABILIZERS CLEARANT, INC. (US) 2003-04-03 WO disclosed
WO-2003026704-A1 METHODS OF STERILIZING BIOLOGICAL MIXTURES USING STABILIZER MIXTURES CLEARANT, INC. (US) 2003-04-03 WO disclosed
US-20030059338-A1 Methods for sterilizing biological materials using flavonoid/flavonol stabilizers CLEARANT, INC. 2003-03-27 US disclosed
US-20030012687-A1 Methods of sterilizing biological materials CLEARANT, INC. 2003-01-16 US disclosed
EP-0290442-A4 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. CHEMEX PHARMACEUTICALS INC (US) 1990-07-03 EP disclosed
WO-1990006104-A1 USE OF KAEMPFEROL AND CERTAIN DERIVATIVES THEREOF FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION LVMH RECHERCHE (FR) 1990-06-14 WO disclosed
EP-0290442-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-11-17 EP disclosed
US-4774229-A ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT CHEMEX PHARMACEUTICALS, INC. (US) 1988-09-27 US disclosed
WO-1988003805-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 WO disclosed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 WO disclosed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221517-A1 Biologically Active Compounds MPO, CAT, CTSA POLH 1790/4885CYP3A4 1575/4885CYP2D6 1355/4885
US-20190231739-A1 NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY CDH1, SMAD3, SMAD2 POLH 4729/4885CYP3A4 1926/4885CYP2D6 3488/4885
US-20200323816-A1 KAEMPFEROL ANALOG-CONTAINING COMPOSITION MYOF, VEGFA, KTN1 POLH 400/4885CYP3A4 629/4885CYP2D6 3524/4885
US-20210228540-A1 KAEMPFEROL ANALOG-CONTAINING COMPOSITION MYOF, KTN1, KIF18A POLH 292/4885CYP3A4 854/4885CYP2D6 3515/4885
US-20090036519-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGAND AND PROCESS FOR PRODUCING THE SAME PPARG, PPARA, PPARD POLH 3069/4885CYP3A4 1011/4885CYP2D6 1911/4885
US-10744113-B2 Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity CDH1, SMAD3, SMAD2 POLH 4767/4885CYP3A4 1435/4885CYP2D6 3185/4885
US-20260117236-A1 METHODS AND COMPOSITIONS FOR MODULATING TRICHOME DENSITY AND FLAVOR MOLECULE SECRETION TAS2R50, TAS2R30, TAS2R31 POLH 2288/4885CYP3A4 2043/4885CYP2D6 2495/4885
US-20050042311-A1 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells ACHE, CHAT, NOTUM POLH 3904/4885CYP3A4 3221/4885CYP2D6 3559/4885
US-20170239211-A1 USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY CDH1, SMAD3, SMAD2 POLH 4767/4885CYP3A4 1435/4885CYP2D6 3185/4885
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities STUB1, SAMM50, CD14 POLH 1173/4885CYP3A4 1640/4885CYP2D6 1252/4885
US-10744114-B2 Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity SMAD2, CDH1, SMAD3 POLH 4834/4885CYP3A4 2771/4885CYP2D6 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.